Reimagining Medicine Q2 2023 Results slide image

Reimagining Medicine Q2 2023 Results

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology Oncology Conclusions Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 65 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation